Vascular Biogenics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Vascular Biogenics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	23.7%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vascular Biogenics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:VBLT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2023	0	-16	-18	-18	N/A
3/31/2023	1	-25	-25	-25	N/A
12/31/2022	1	-32	-32	-32	N/A
9/30/2022	1	-38	-33	-32	N/A
6/30/2022	1	-35	-33	-32	N/A
3/31/2022	1	-34	-29	-27	N/A
12/31/2021	1	-30	-26	-25	N/A
9/30/2021	1	-28	-26	-25	N/A
6/30/2021	1	-27	-23	-22	N/A
3/31/2021	1	-25	-24	-23	N/A
12/31/2020	1	-24	-23	-23	N/A
9/30/2020	1	-23	-21	-21	N/A
6/30/2020	1	-22	-21	-21	N/A
3/31/2020	1	-21	-16	-16	N/A
12/31/2019	1	-19	-13	-13	N/A
9/30/2019	1	-18	-12	-12	N/A
6/30/2019	1	-18	-13	-13	N/A
3/31/2019	1	-17	-16	-15	N/A
12/31/2018	1	-20	-18	-16	N/A
9/30/2018	14	-10	-7	-2	N/A
6/30/2018	14	-11	-8	-1	N/A
3/31/2018	14	-12	-10	-2	N/A
12/31/2017	14	-10	-10	-4	N/A
9/30/2017	N/A	-21	-22	-18	N/A
6/30/2017	N/A	-18	-18	-17	N/A
3/31/2017	N/A	-16	N/A	-15	N/A
12/31/2016	N/A	-16	N/A	-13	N/A
9/30/2016	N/A	-14	N/A	-14	N/A
6/30/2016	N/A	-17	N/A	-15	N/A
3/31/2016	N/A	-17	N/A	-15	N/A
12/31/2015	N/A	-15	N/A	-13	N/A
9/30/2015	N/A	-17	N/A	-12	N/A
6/30/2015	N/A	-15	N/A	-13	N/A
3/31/2015	N/A	-15	N/A	-13	N/A
12/31/2014	N/A	-17	N/A	-14	N/A
9/30/2014	N/A	-18	N/A	-15	N/A
12/31/2013	N/A	-17	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VBLT's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if VBLT's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if VBLT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if VBLT's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if VBLT's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VBLT's Return on Equity is forecast to be high in 3 years time

Vascular Biogenics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased to US$6.00

Consensus forecasts updated

Consensus forecasts updated

No longer forecast to breakeven

Consensus forecasts updated

Forecast to breakeven in 2024

Recent updates

Vascular Biogenics Ltd.(NasdaqCM:VBLT) dropped from NASDAQ Composite Index

Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. (NasdaqGM:VBLT) from Aurum Ventures MKI Ltd. and others in reverse merger transaction.

Vascular Biogenics Ltd. Approves Board Appointments

Vascular Biogenics Ltd. Receives Non-Compliance Notice from Nasdaq

Full year 2022 earnings released: US$0.42 loss per share (vs US$0.45 loss in FY 2021)

An unknown buyer entered into an agreement to acquire Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd. (NasdaqGM:VBLT) for $7.1 million.

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

VBL Therapeutics receives non-compliance letter from Nasdaq

VBL Therapeutics GAAP EPS of -$0.12

VBL Therapeutics Announces Workforce Reduction

Price target increased to US$6.00

Vbl Therapeutics Announces Top-Line Data from Phase 3 Oval Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Vascular Biogenics Ltd., Annual General Meeting, Jul 07, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Ltd. to Report Q1, 2022 Results on May 17, 2022

Consensus forecasts updated

No longer forecast to breakeven

VBL Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation for Ofra-Vec (Ofranergene Obadenovec or VB-111) in Combination with Paclitaxel for Treatment of Platinum-Resistant Ovarian Cancer

Consensus forecasts updated

VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

Forecast to breakeven in 2024

Vascular Biogenics Ltd. announced that it expects to receive €15 million in funding from European Innovation Council

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.12 loss in 3Q 2020)

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the Oval Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

High number of new directors

VBL Therapeutics Provides Update on Oval, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Announces Addition of Progression Free Survival as A Second Primary Endpoint in OVAL, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

Vbl Therapeutics to Provide an Update on the Oval Phase 3 Registration Enabling Study of Vb-111 in Ovarian Cancer At the 2021

Price target increased to US$5.20

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: US$0.56 loss per share (vs US$0.54 loss in FY 2019)

Vascular Biogenics Ltd. to Report Q4, 2020 Results on Mar 25, 2021

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

New 90-day high: US$2.50

Price target raised to US$4.50

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

VBL Therapeutics expands the ovarian cancer trial in Europe

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.96

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2020 earnings released: US$0.12 loss per share

Revenue and earnings miss expectations

VBL Therapeutics EPS beats by $0.01, misses on revenue

New 90-day low: US$1.07

Vascular Biogenics Ltd. to Report Q3, 2020 Results on Nov 16, 2020

Vascular Biogenics Ltd. Announces Resignation of Susan Kelley as an Independent Director

Vascular Biogenics Ltd. Announces Board Changes

New 90-day low - US$1.16

First half earnings released

Vascular Biogenics Ltd. to Report Q2, 2020 Results on Aug 13, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies